Education
About Us
Working with TipRanks
Follow Us
Inovio Pharmaceuticals (INO)
NASDAQ:INO
INO Stock Chart & Stats
$1.52
-$0.22(-9.65%)
At close: 4:00 PM EST
$1.52
-$0.22(-9.65%)
Day’s Range― - ―
52-Week Range$1.30 - $2.98
Previous CloseN/A
Volume1.36M
Average Volume (3M)1.84M
Market Cap
$104.43M
Enterprise Value$54.91M
Total Cash (Recent Filing)$50.80M
Total Debt (Recent Filing)$10.02M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Mar 03, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding68,703,380
10 Day Avg. Volume1,961,442
30 Day Avg. Volume1,840,048
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.73
Price to Sales (P/S)228.26
P/FCF Ratio-0.48
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue301.14
Enterprise Value/Gross Profit-41.13
Enterprise Value/Ebitda-0.52
Forecast
1Y Price Target
$7.33Price Target Upside382.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.52
Revenue Forecast (FY)$15.97M
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationINO-3107's regimen does not require surgical removal of papillomas during dosing, offering a less invasive option that could encourage physician adoption and improve patient experience compared with existing RRP therapies.
Durable EfficacyLong-term evidence showing sustained reductions in the need for surgery supports a durable clinical benefit that can bolster prescriber confidence and reimbursement discussions.
Second-in-class Market OpportunityPositioning as a potential second RRP treatment with a non-surgical approach creates a clear pathway to capture patients in a specialized market segment.
Bears Say
Accounting-driven VolatilityMaterial fair value changes in warrant liabilities have produced earnings volatility that complicates financial forecasting and may weigh on investor confidence.
Funding PressureA larger-than-expected operating loss driven by accounting adjustments increases the likelihood that the company will need to raise new capital in the near term, creating dilution risk for current investors.
Regulatory UncertaintyFDA feedback that submitted information may not justify accelerated approval eligibility raises the risk of additional data requests or an extended review process, which could delay potential approval.
Inovio Pharmaceuticals News
INO FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $1.30 and its highest was $2.98 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $104.43M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Mar 03, 2026 which is in 43 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of -$0.422 by -$0.448.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals pays a Monthly dividend of $0.069 which represents an annual dividend yield of N/A. See more information on Inovio Pharmaceuticals dividends here
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.38.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 68,703,380 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.87 in its last earnings report, missing expectations of -$0.422. Following the earnings report the stock price went down -6.977%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in INO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inovio Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.33 (382.24% Upside)
$7.33 (382.24% Upside)
Blogger Sentiment
Bullish
INO Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 10.5%
Last 30 Days ▲ 10.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.41%
12-Months-Change
Fundamentals
Return on Equity
-328.45%
Trailing 12-Months
Asset Growth
-35.19%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
INO Company Deck
INO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant milestones such as the BLA submission for INO-3107 and cost management achievements. However, challenges persist with increased net loss and reduced cash reserves. Progress in clinical trials and pipeline advancements are promising, but financial constraints pose concerns.View all INO earnings summariesINO Stock 12 Month Forecast
Average Price Target
$7.33
▲(382.24% Upside)
Technical Analysis
Ownership Overview
0.42% Insiders
4.35% Mutual Funds
0.12% Other Institutional Investors
91.04% Public Companies and
Individual Investors